Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally.
+ 1 more risk
Good value with questionable track record.
Share Price & News
How has Wanbury's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: WANBURY's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: WANBURY exceeded the Indian Pharmaceuticals industry which returned 46.8% over the past year.
Return vs Market: WANBURY exceeded the Indian Market which returned 2.5% over the past year.
Price Volatility Vs. Market
How volatile is Wanbury's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall StImagine Owning Wanbury (NSE:WANBURY) While The Price Tanked 64%
4 months ago | Simply Wall StWhat Type Of Shareholder Owns Wanbury Limited's (NSE:WANBURY)?
6 months ago | Simply Wall StSuch Is Life: How Wanbury (NSE:WANBURY) Shareholders Saw Their Shares Drop 68%
Is Wanbury undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: WANBURY (₹37.85) is trading below our estimate of fair value (₹187.96)
Significantly Below Fair Value: WANBURY is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: WANBURY is good value based on its PE Ratio (1.4x) compared to the IN Pharmaceuticals industry average (22.9x).
PE vs Market: WANBURY is good value based on its PE Ratio (1.4x) compared to the Indian market (13.9x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate WANBURY's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: WANBURY has negative assets, so we can't compare its PB Ratio to the IN Pharmaceuticals industry average.
How is Wanbury forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Wanbury has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine whether Wanbury is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- Wanbury competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Wanbury performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: WANBURY has a large one-off gain of ₹826.4M impacting its March 31 2020 financial results.
Growing Profit Margin: WANBURY became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: WANBURY has become profitable over the past 5 years, growing earnings by -2.4% per year.
Accelerating Growth: WANBURY has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: WANBURY has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.6%).
Return on Equity
High ROE: WANBURY's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Wanbury's financial position?
Financial Position Analysis
Short Term Liabilities: WANBURY has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: WANBURY has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: WANBURY has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: WANBURY's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: WANBURY's debt is well covered by operating cash flow (35.5%).
Interest Coverage: WANBURY's interest payments on its debt are not well covered by EBIT (0.4x coverage).
What is Wanbury current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate WANBURY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate WANBURY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if WANBURY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if WANBURY's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: WANBURY is not paying a notable dividend for the Indian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of WANBURY's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Wanbury has no CEO, or we have no data on them.
|Vice Chairman||no data||no data||no data|
|Chief Financial Officer||4.33yrs||₹13.98m||no data|
|Compliance Officer & Company Secretary||5.25yrs||₹3.10m||no data|
|President of Operations - API Business||2.92yrs||₹12.17m||no data|
|Senior Vice President of QA||no data||no data||no data|
Experienced Management: WANBURY's management team is considered experienced (4.3 years average tenure).
|Vice Chairman||no data||no data||no data|
|Non-Executive Independent Director||7.25yrs||₹364.00k||no data|
|Non-Executive Independent Director||15.42yrs||₹460.00k||no data|
|Non-Executive Independent Woman Director||1.5yrs||₹100.00k||no data|
Experienced Board: WANBURY's board of directors are considered experienced (7.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.4%.
Wanbury Limited's company bio, employee growth, exchange listings and data sources
- Name: Wanbury Limited
- Ticker: WANBURY
- Exchange: NSEI
- Founded: 1988
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹933.568m
- Shares outstanding: 25.00m
- Website: https://www.wanbury.com
Number of Employees
- Wanbury Limited
- BSEL Tech Park, B-Wing
- 10th Floor
- Navi Mumbai
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|524212||BSE (Mumbai Stock Exchange)||Yes||Equity Shares||IN||INR||Feb 2005|
|WANBURY||NSEI (National Stock Exchange of India)||Yes||Equity Shares||IN||INR||Feb 2005|
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for gynecology, orthopedics, heamatinics, anti- ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/10 12:51|
|End of Day Share Price||2020/08/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.